Three oral GLP-1 options exist in 2026: Rybelsus (oral semaglutide, approved 2019 for type 2 diabetes), an oral semaglutide formulation for weight management approved in early 2026, and Foundayo (orforglipron), Eli Lilly's small-molecule agent approved April 1, 2026 for chronic weight management at $149 per month through LillyDirect
Research on exercise recovery appears promising, particularly for reducing muscle soreness
If you notice heartburn after chocolate, treat it as a possible contributor and track it alongside other variables, rather than assuming it is the sole culprit
Oftentimes, vital signs and history-taking can be complex, especially in hospice settings
Home Injectable products Lipolitics PROF